{"analyses":[{"ciLowerLimit":"0.352","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.647","groupDescription":"TC2/3 or IC2/3 Subgroup","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.471","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.386","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.639","groupDescription":"TC1/2/3 or IC1/2/3 Subgroup","groupIds":["OG000","OG001"],"nonInferiorityComment":"Stratified Analysis","nonInferiorityType":"SUPERIORITY","pValue":"<.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.486","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"13.0","value":"11.1"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"7.7","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"115"}],"units":"Participants"}],"title":"TC2/3 or IC2/3 Subgroup"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"12.5","value":"11.0"},{"groupId":"OG001","lowerLimit":"5.8","upperLimit":"7.3","value":"6.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"title":"TC1/2/3 or IC1/2/3 Subgroup"}],"denoms":[{"counts":[{"groupId":"OG000","value":"190"},{"groupId":"OG001","value":"164"}],"units":"Participants"}],"description":"PFS as Determined by the Investigator according to RECIST v1.1, in Arm B Versus Arm C by PD-L1 Subgroup: TC2/3 or 1C2/3 and TC1/2/3 or IC1/2/3 (ITT-WT Population)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IV infusion of atezolizumab and bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of atezolizumab until loss of clinical benefit and bevacizumab until progressive disease, unacceptable toxicity, or death during maintenance treatment phase.","id":"OG000","title":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)"},{"description":"Participants received IV infusion of bevacizumab on Day 1 of each 21-day cycle followed by IV infusion of paclitaxel and carboplatin on Day 1 of each 21-day cycle for 4 or 6 cycles or loss of clinical benefit whichever occurs first, during induction treatment phase. Participants received IV infusion of bevacizumab during maintenance treatment phase until progressive disease, unacceptable toxicity, or death.","id":"OG001","title":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)"}],"paramType":"MEDIAN","populationDescription":"The PD-L1-selected WT populations are defined as the PD-L1-selected populations (TC2/3 or IC2/3 population or TC1/2/3 or IC1/2/3 population) excluding patients with a sensitizing EGFR mutation or ALK translocation.","reportingStatus":"POSTED","timeFrame":"Baseline until disease progression or death, whichever occurs first (up to approximately 29 months)","title":"PFS, as Determined by the Investigator in Arm B Versus Arm C by PD-L1 Subgroup","type":"SECONDARY","unitOfMeasure":"Months"}